- Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position
- Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™
- Invivyd Announces CEO Transition
- Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
- Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
- Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial
- Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
- Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents
- Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
More ▼
Key statistics
As of last trade, Invivyd Inc (IVVD:NMQ) traded at 2.10, 113.73% above the 52 week low of 0.9802 set on Jun 23, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.22 |
---|---|
High | 2.24 |
Low | 2.07 |
Bid | 2.09 |
Offer | 2.10 |
Previous close | 2.08 |
Average volume | 750.89k |
---|---|
Shares outstanding | 119.22m |
Free float | 97.51m |
P/E (TTM) | -- |
Market cap | 247.98m USD |
EPS (TTM) | -1.81 USD |
Data delayed at least 15 minutes, as of Apr 30 2024 16:12 BST.
More ▼